Signaling Pathways
-
A2917 FlumazenilTarget: GABAA ReceptorsSummary: Benzodiazepine antagonist
-
A1958 EtomidateTarget: GABAA ReceptorsSummary: General anesthetic with GABA modulatory and GABA-mimetic actions
-
A1888 TRAM-34Target: Calcium-Activated Potassium (KCa) ChannelsSummary: KCa3.1 blocker,potent and highly selective
-
A1855 BumetanideTarget: Na /K /Cl- Symporters (NKCCs)Summary: NKCC cotransporter inhibitor
-
A5354 ZonisamideTarget: Voltage-gated Sodium (NaV) Channels|Voltage-gated Calcium Channels (CaV)|Carbonic Anhydrases|Calcium-Activated Potassium (KCa) ChannelsSummary: Antiepileptic with anticonvulsant and mechanistic effect
-
A1174 AMG-517Target: TRP ChannelSummary: TRPV1 antagonist,potent and highly selective
-
A8349 Omecamtiv mecarbilTarget: MyosinSummary: Cardiac myosin activator
-
A8435 FurosemideTarget: Na /K /Cl- Symporters (NKCCs)|GABAA ReceptorsSummary: GABAA receptors antagonist
-
A8436 GabapentinSummary: GABA enhancer
-
A8513 RiluzoleTarget: Voltage-gated Sodium (NaV) Channels|glutamate releaseSummary: Sodium channel protein inhibitor